Testimony of Charles Halpern, Public Interest Attorney and Member, Institute of Medicine of the National Academy of Sciences
By Charles Halpern,
Testimony to California Senate Subcommittee
| 03. 09. 2005
Oversight Hearing on the Implementation of Proposition 71, the Stem Cell Research and Cures Act
Joint Hearing of the California Senate Subcommittee on Stem Cell Research Oversight, Senate Health Committee, and Assembly Health Committee
Testimony of Charles Halpern, Public Interest
Attorney and Member, Institute of Medicine of the National Academy
of Sciences
Oversight Hearing on the Implementation of Proposition 71,
the Stem Cell Research and Cures Act
Joint Hearing of the California Senate Subcommittee on Stem
Cell Research Oversight, Senate Health Committee, and Assembly
Health Committee
March 9, 2005
SUMMARY
This Oversight Hearing is an important milestone in the California
effort to assume leadership in the field of stem cell research.
Active legislative engagement with the California Institute
for Regenerative Medicine (CIRM) is essential for this initiative
to succeed.
The Independent Citizen’s Oversight Committee (ICOC) has
met four times since the passage of Proposition 71. While the
ICOC has made some important decisions, it still must lay a
solid foundation for its grants program. Grant guidelines and
an operating budget must be developed. The conflict of interest
problem, which affects all aspects of the ICOC process, must
be addressed in a serious fashion.
I encourage the Senate Oversight Subcommittee to take the following
steps:
Establish a regular schedule of oversight hearings, every two
or...
Related Articles
By Katherine Long, Ben Foldy, and Lingling Wei, The Wall Street Journal | 12.13.2025
Inside a closed Los Angeles courtroom, something wasn’t right.
Clerks working for family court Judge Amy Pellman were reviewing routine surrogacy petitions when they spotted an unusual pattern: the same name, again and again.
A Chinese billionaire was seeking parental...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Sarah Kliff, The New York Times | 12.10.2025
Micah Nerio had known since his early 30s that he wanted to be a father, even if he did not have a partner. He spent a decade saving up to pursue surrogacy, an expensive process where he would create embryos...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
